Tarlatzis B, Tavmergen E, Szamatowicz M, Barash A, Amit A, Levitas E, Shoham Z
Unit for Human Reproduction, Aristotle University of Thessaloniki and Infertility & IVF Centre, Geniki Kliniki, Thessaloníki, Greece.
Hum Reprod. 2006 Jan;21(1):90-4. doi: 10.1093/humrep/dei293. Epub 2005 Sep 19.
The effect of recombinant human LH (r-hLH; lutropin alfa) in women undergoing controlled ovarian stimulation with recombinant human FSH (r-hFSH) prior to IVF was investigated.
After down-regulation with the GnRH agonist, buserelin, 114 normo-ovulatory women (aged 18-37 years) received r-hFSH alone until the lead follicle reached a diameter of 14 mm. Patients were then randomized in a double-blind fashion to receive r-hFSH in addition to r-hLH, 75 IU s.c., or placebo daily for a maximum of 10 days prior to oocyte retrieval and IVF. The primary end-point was the number of metaphase II oocytes.
There were no significant differences between treatment groups for the primary end-point. Serum estradiol concentrations on the day of HCG administration were significantly higher in the group receiving r-hLH plus r-hFSH than in the group receiving r-hFSH alone (P = 0.0001), but there were no significant differences between the groups in dose and duration of r-hFSH treatment required, oocyte maturation, fertilization rate, pregnancy rate and live birth rate.
In this patient population, the addition of r-hLH during the late follicular phase of a long GnRH agonist and r-hFSH stimulation cycle provides no further benefit in terms of oocyte maturation or other end-points.
研究了重组人促黄体生成素（r-hLH；注射用重组人促黄体激素）对在体外受精（IVF）前接受重组人促卵泡激素（r-hFSH）进行控制性卵巢刺激的女性的影响。
在用促性腺激素释放激素（GnRH）激动剂布舍瑞林进行降调节后，114名排卵正常的女性（年龄18 - 37岁）单独接受r-hFSH，直至主导卵泡直径达到14毫米。然后，患者以双盲方式随机分组，在取卵和IVF前最多10天，除r-hFSH外，每天额外接受75 IU皮下注射的r-hLH或安慰剂。主要终点是中期II卵母细胞的数量。
治疗组之间的主要终点无显著差异。在注射人绒毛膜促性腺激素（HCG）当天，接受r-hLH加r-hFSH的组血清雌二醇浓度显著高于单独接受r-hFSH的组（P = 0.0001），但在所需r-hFSH治疗的剂量和持续时间、卵母细胞成熟、受精率、妊娠率和活产率方面，两组之间无显著差异。
在该患者群体中，在长效GnRH激动剂和r-hFSH刺激周期的卵泡晚期添加r-hLH，在卵母细胞成熟或其他终点方面没有进一步益处。
